1-3 of 3
Celine Wilke, MD
Close
Sort by
Journal Articles

Preclinical Rationale for the Use of Crizanlizumab (SEG101) in Myelofibrosis

Paola Verachi, Fabrizio Martelli, PhD, Maria Zingariello, PhD, Shalini Chaturvedi, Celine Wilke, MD, Valerie Campello-Iddison, MD, Anna Rita Migliaccio, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 26–27.
https://doi.org/10.1182/blood-2020-133896
Published: 2020
Journal Articles

Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis

Andrew Charles Perkins, MBBS,PhD, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Thomas Lehmann, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Andreas Reiter, MD, Vikas Gupta, MD FRCP, FRCPath, Claire Harrison, DM, FRCP, FRCPath, Jean-Jacques Kiladjian, MD PhD, Alessandro M. Vannucchi, MD, Marielle Wondergem, MD, Robert Pack, PhD, Monika Wroclawska, MD, Celine Wilke, MD, Angela Zhang, PhD, Florian H. Heidel, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 52–53.
https://doi.org/10.1182/blood-2020-140408
Published: 2020
Journal Articles

Biomarker Analysis in Patients (pts) with Steroid-Refractory Acute Graft-Vs-Host Disease (aGVHD) Treated with Ruxolitinib (RUX) or Best Available Therapy (BAT) in the Randomized, Phase 3 REACH2 Study

Gérard Socié, MD PhD, Dietger Niederwieser, MD PhD, Nikolas Von Bubnoff, Mohamad Mohty, MD PhD, Jeffrey Szer, MBBS, Reuven Or, MD, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Eva Maria Wagner, MD, Edouard Forcade, MD PhD, Jaime Sanz Caballer, MD PhD, Domenico Russo, MD, Giovanni Grillo, MD, Tsila Zuckerman, MD, Sinem Civriz Bozdag, MD, David Ritchie, MD ChB, PhD FRACP, FRCPA, Shalini Chaturvedi, Anirudh Prahallad, PhD, Karen Sinclair, PhD, Celine Wilke, MD, Robert Zeiser, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 26–27.
https://doi.org/10.1182/blood-2020-140403
Published: 2020